Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir.

摘要: Abstract Introduction Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads immune activation. We aimed establish if expression in liver tissue plasma chronic hepatitis B (CHB) patients correlated with each other further investigate levels before during therapy peginterferon adefovir could predict treatment outcome CHB patients. Patients methods A total 86 (41 HBeAg-positive 45 HBeAg-negative) received combination for 48 weeks. Combined Response (CR) (HBeAg-negativity, HBV-DNA ≤ 2000 IU/mL, ALT normalization) non-response (NR) were assessed at Week 72. Plasma measured baseline Day 3 (D3) 1 (W1). Pre-treatment biopsies from 40 obtained stored liquid nitrogen the analysis intrahepatic mRNA expression. Results CR was achieved 14/41 17/45 HBeAg-negative Mean significantly higher than NR (3.20 vs 3.00 log pg/mL p = 0.03); but not Baseline ALT-levels -negative (both p  Conclusions are other, suggesting that reflects Higher seem be associated treated adefovir,